PRRSQ^TM－Product features

The PRRSQ^TM vaccine is the 1st commercial subunit vaccine for Porcine Reproductive and Respiratory Syndrome (PRRS) in the world. Through its unique antigen delivery platform, PRRSQ^TM could induce both significant humoral and cell-mediated immune responses against PRRS virus, and promote CMI response rapidly and persistently. This subunit vaccine has demonstrated excellent induction of swine immune responses. It also has a safety profile that is superior to the current PRRS vaccines in the world.
The features of the vaccine are:
1. Uses the Pseudomonas exotoxin A as an antigen delivery platform
2. Induces both humoral and cell-mediated immune responses
3. Intercepts the epitope of neutralization antibody titration in PRRSV virus, and thus effectively reduce ADE (Antibody Dependent Enhancement).
4. Includes both North American strain and the European strain of the PRRS antigen
5. Significantly reduces the morbidity and mortality caused by PRRSV
6. Does not induce allergic or immunotoxic reactions in lungs or skin.

• Field trials show that PRRSQ^TM is safe and effective

1. Significant reduction of abortion rate, stillbirth and reductive failure caused by PRRSV
2. Significant improvements in livability at birth, the average litter size, litter weight of newborn piglets
3. Significant reduction in levels and duration of viremia
4. Significant reduction of PRRS-induced lung lesions; gross & microscopic
5. Improve the growth performance of piglets
6. Provides good protection to sows and piglets

• Packaging：50 dose/vial